Experimental Therapeutics
Scientists at Novartis detail research in experimental therapeutics
Published in Drug Law Weekly, May 8th, 2007
Current study results from the report, "GABAB receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DeltaFosB accumulation," have been published. According to recent research from Basel, Switzerland, "There is an increasing demand for a novel non-nicotinic, nondopaminergic therapeutic approach to nicotine addiction. GABAergic mechanisms have been implicated in drug dependence."
"Recently, a novel GABAB receptor allosteric-positive modulator, GS39783, was characterized. There are no investigations to date on the effects of GABAB receptor-positive modulators in animal models of nicotine...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-05-08)
More Articles from Drug Law Weekly
- Allergies
Allergy & Asthma Network Mothers of Asthmatics Exposes Potentially Dangerous Asthma Medications - Arthritis
Former Building Cleaner Confronts J&J About Access to Health Care, Drugs - Biotech Business
Spherix Signs Letter of Intent for the Sale of Its Information Subsidiary - Drug Delivery
OctoPlus obtains full rights to PolyActive drug delivery technology from IsoTis - Drug Development
Express Scripts' Workers' Compensation Program Increases Use of Generic Drugs - Drug Development
Recent studies from National Board of Forensic Medicine add new data to drug development - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
